logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • AstraZeneca Pharmaceuticals LP drugs

    FiltersReset Filters
    33 results

    • airsupra - albuterol sulfate and budesonide aerosol, metered

      (Albuterol Sulfate And Budesonide)
      Astrazeneca Pharmaceuticals Lp

    • andexxa - andexanet alfa injection, powder, lyophilized, for solution

      (Andexanet Alfa)
      Astrazeneca Pharmaceuticals Lp

    • bevespi aerosphere

      (Glycopyrrolate and formoterol fumarate)
      AstraZeneca Pharmaceuticals LP
      Usage: BEVESPI AEROSPHERE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for acute bronchospasm relief or asthma treatment.

    • breztri - budesonide, glycopyrrolate, and formoterol fumarate aerosol, metered

      (Budesonide, Glycopyrrolate, And Formoterol Fumarate)
      Astrazeneca Pharmaceuticals Lp

    • brilinta

      (Ticagrelor)
      AstraZeneca Pharmaceuticals LP
      Usage: BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction, as well as for those with high-risk coronary artery disease. It also decreases stroke risk in patients with acute ischemic stroke or transient ischemic attack.

    • budesonide and formoterol fumarate dihydrate

      (Budesonide and Formoterol Fumarate Dihydrate)
      AstraZeneca Pharmaceuticals LP
      Usage: Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol is indicated for asthma treatment in patients aged 6 and older and for the maintenance treatment of COPD. It is used for patients not adequately controlled on asthma medications or requiring both an ICS and LABA, but not for acute bronchospasm relief.

    • byetta - exenatide injection

      (Exenatide)
      Astrazeneca Pharmaceuticals Lp

    • calquence

      (acalabrutinib)
      AstraZeneca Pharmaceuticals LP
      Usage: CALQUENCE is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplantation, previously treated MCL patients, and those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    • crestor

      (Rosuvastatin)
      AstraZeneca Pharmaceuticals LP
      Usage: CRESTOR is indicated for reducing the risk of major cardiovascular events in adults at increased risk, as an adjunct to diet for lowering LDL cholesterol in various hyperlipidemias, and for treating primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It is also used in pediatric patients with familial hypercholesterolemia.

    • daliresp

      (roflumilast)
      AstraZeneca Pharmaceuticals LP
      Usage: DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD linked to chronic bronchitis and a history of exacerbations. It is not a bronchodilator and should not be used for acute bronchospasm relief. The initial dose is 250 mcg for the first four weeks only.